Royalty Pharma (RPRX) Q3 Earnings and Revenues Surpass Estimates

Nov 6, 2024 · Royalty Pharma (RPRX) delivered earnings and revenue surprises of 9.47% and 3.39%, respectively, for the quarter ended September 2024. Do the numbers hold clues to …

47%
OFF

Royalty Pharma (RPRX) Q3 Earnings And Revenues Surpass Estimates

2 weeks from now

Nov 6, 2024 · Royalty Pharma (RPRX) delivered earnings and revenue surprises of 9.47% and 3.39%, respectively, for the quarter ended September 2024. Do the numbers hold clues to …

zacks.com

$1.04
OFF

Royalty Pharma (RPRX) Q3 Earnings And Revenues Surpass Estimates

2 weeks from now

Nov 6, 2024 · Royalty Pharma (RPRX) came out with quarterly earnings of $1.04 per share, beating the Zacks Consensus Estimate of $0.95 per share. This compares to earnings of …

nasdaq.com

82%
OFF

Royalty Pharma (RPRX) Surpasses Q3 Earnings And Revenue …

2 weeks from now

Nov 8, 2022 · Royalty Pharma (RPRX) delivered earnings and revenue surprises of 2.82% and 3.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to …

yahoo.com

4%
OFF

Compared To Estimates, Royalty Pharma (RPRX) Q3 Earnings: A

2 weeks from now

Nov 6, 2024 · Royalty Pharma (RPRX) reported $735 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 15.4%. EPS of $1.04 for the same …

nasdaq.com

$0.73
OFF

Royalty Pharma (RPRX) Surpasses Q3 Earnings And Revenue …

2 weeks from now

Nov 8, 2022 · Royalty Pharma (RPRX) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of …

nasdaq.com

$735
OFF

Compared To Estimates, Royalty Pharma (RPRX) Q3 Earnings: A …

2 weeks from now

Nov 6, 2024 · Royalty Pharma (RPRX Quick Quote RPRX - Free Report) reported $735 million in revenue for the quarter ended September 2024, representing a year-over-year increase of …

zacks.com

$1.04
OFF

Royalty Pharma (RPRX) Q3 Earnings And Revenues Surpass Estimates

2 weeks from now

Nov 6, 2024 · Royalty Pharma (RPRX) came out with quarterly earnings of $1.04 per share, beating the Zacks Consensus Estimate of $0.95 per share. This compares to earnings of …

reportify.ai

$1
OFF

Logo Royalty Pharma

2 weeks from now

Biopharma revenues (2033e) >$1 trillion(1) ... Gilead Q3 earnings call transcript, November 6, 2024. 5. Royalty Pharma estimate based on the Johnson and Johnson May 2024 filing date …

royaltypharma.com

$2
OFF

Royalty Pharma Sees FY24 Revenue $2.8B, Consensus $2.65B

2 weeks from now

5 days ago · Based on preliminary unaudited fourth quarter 2024 results, Royalty Pharma (RPRX) now expects to deliver Portfolio Receipts for full year 2024 of approximately $2,800 million, …

businessinsider.com

$537
OFF

Royalty Pharma To Highlight Accomplishments And Provide …

2 weeks from now

4 days ago · Earnings Flash (RPRX) ROYALTY PHARMA Posts Q2 Revenue $537M, vs. Street Est of $645.3M 24-08-08: MT Royalty Pharma plc Reports Earnings Results for the Second …

marketscreener.com

$3
OFF

Royalty Pharma To Buy Its External Manager, Announces $3B Share …

2 weeks from now

4 days ago · Royalty Pharma plc (RPRX) Q3 2024 Earnings Call Transcript; ... Royalty Pharma Q3 2024 Earnings Preview; Syndax, Royalty Pharma enter into $350M royalty funding deal; …

seekingalpha.com

3%
OFF

Unveiling Royalty Pharma (RPRX) Q3 Outlook: Wall Street …

2 weeks from now

Nov 1, 2024 · In its upcoming report, Royalty Pharma (RPRX) is predicted by Wall Street analysts to post quarterly earnings of $0.95 per share, reflecting an increase of 20.3% compared to the …

nasdaq.com

15%
OFF

Royalty Pharma Q3 Soars: 15% Revenue Growth, $1.2B …

2 weeks from now

Nov 6, 2024 · Royalty Pharma (RPRX) reported strong Q3 2024 results with Portfolio Receipts growing 15% to $735 million and net cash from operations reaching $704 million.The company …

stocktitan.net

FAQs about Royalty Pharma (RPRX) Q3 Earnings and Revenues Surpass Estimates Coupon?

What is Royalty Pharma's liquidity and capital resources?

Royalty Pharma’s liquidity and capital resources are summarized below: As of September 30, 2024, Royalty Pharma had cash and cash equivalents of $950 million and total debt with principal value of $7.8 billion. During the third quarter of 2024, Royalty Pharma repurchased approximately three million Class A ordinary shares for $95 million. ...

How many Class A shares has Royalty Pharma repurchased?

Through the first nine months of 2024, Royalty Pharma has repurchased approximately seven million Class A ordinary shares for $180 million. The weighted-average number of diluted Class A ordinary shares outstanding for the third quarter of 2024 was 593 million as compared to 601 million for the third quarter of 2023. ...

How did Royalty Pharma perform in the third quarter of 2024?

“We delivered strong growth of approximately 15% in Portfolio Receipts in the third quarter of 2024 and are delighted to raise our full year guidance” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. ...

What are the estimate revisions trend for Royalty Pharma?

Ahead of this earnings release, the estimate revisions trend for Royalty Pharma: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. ...

Is Royalty Pharma plc acquiring new royalties?

The company has been active in acquiring new royalties, with a capital deployment of approximately $2.6 billion year-to-date. Royalty Pharma PLC (NASDAQ:RPRX) raised its full-year 2024 guidance, expecting portfolio receipts between $2.75 billion and $2.8 billion. ...

What is Royalty Pharma's Financial Guidance for 2024?

Raising financial guidance for full year 2024 (excludes contribution from future transactions) Royalty Pharma now expects 2024 Portfolio Receipts to be between $2,750 million and $2,800 million (previously between $2,700 million and $2,775 million). ...